Types autonomous agents

In conclusion, the incorporation of an acetylenic moiety into a benzylamine structure conferred completely novel biochemical and therapeutic properties on an otherwise inert phenylalkylamine. Outstanding in this respect are the potent MAO-inhibitory, antihypertensive, and antidepressant effects of this new drug. The potent autonomic side effects normally encountered with the ganglionic blocking type antihypertensive agents are much less pronounced with this drug and a definite advance has been scored toward achieving selectivity of action. 

Beta-blockade reduces mortality in patients with heart failure by at least a third when initiated carefully, with gradual dose titration, in those with stable heart failure (34,35). Similarly, beta-blocker prescribing should be encouraged in people with diabetes, since they have a worse outcome after cardiac events and beta-blockade has an independent secondary protective effect (36,37). The small risk of masking metabohc and autonomic responses to hypoglycemia, which was only a problem with non-selective agents in type I diabetes, is a very small price worth paying in diabetics with coronary heart disease. 

SYMPATHOMIMETIC AGENTS mimic the actions of the sympathetic division of the autonomic nervous system. The effects of this system on the tissues and organs are mediated by adrenaline and noradrenaline - which act predominantly as hormone or neurotransmitter, respectively. These catecholamines act at one of two receptor types, a-adrenoceptor and P-adrenoceptor, to exert the actions of the system. Sympathomimetics are of two types. 

---